Rituximab en población pediátrica: experiencia en el tratamiento de enfermedades reumatológicas, en un hospital infantil de Medellín, Colombia

improvement was observed with rituximab in SLE-associated hemolytic anemia and thrombocytopenia associated with SLE and antiphospholipid syndrome, who had not responded to first-line therapy. Although LN showed favorable clinical effect and saving allowed dose steroids, prospective studies are required to evaluate utility in patients with LN ≤18.